Results 181 to 190 of about 1,296,096 (233)
Synthetic cannabinoid receptor agonists: classification and nomenclature
Clinical Toxicology, 2019 Introduction: The emergence of novel psychoactive substances has changed the epidemiology of drugs used recreationally throughout Europe and have posed significant challenges for clinicians, researchers and regulators. Synthetic cannabinoid receptor agonists have made up a large proportion of these novel psychoactive substances.
A J, Potts +3 more
core +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Cannabinoid Receptor Agonists and Antagonists
Current Pharmaceutical Design, 1995Research on the cannabinoid natural products and synthetic drugs has been bolstered recently by major breakthroughs in the understanding of the biochemical pathways and the production of significant new tools in the form of novel chemical structures. Cannabinoid receptors are now defined pharmacologically, anatomically, and at the molecular level as ...
Allyn Howlett, Lawrence S Melvin
exaly +2 more sources
Synthetic Cannabinoid Receptor Agonists (SCRAs)
Abstract Synthetic cannabinoid receptor agonists (SCRAs), originally developed for biomedical research purposes, are now one of the biggest classes of new psychoactive substances (NPS). Due to their higher binding affinity and activity to the cannabinoid receptors, compared to Δ9-THC, they pose a higher pharmacological and ...
Pfeifer, Philippe +1 more
openaire +2 more sources
CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS
Annual Review of Pharmacology and Toxicology, 1998▪ Abstract Marijuana has been in use for over 4000 years as a therapeutic and as a recreational drug. Within the past decade, two cannabinoid receptor types have been identified, their signal transduction characterized, and an endogenous lipid agonist isolated from mammalian tissues.
C C, Felder, M, Glass
openaire +2 more sources
Cannabinoid Receptors and Their Endogenous Agonist, Anandamide
Neurochemical Research, 1998Cannabinoids are a class of compound found in marijuana which have been known for their therapeutic and psychoactive properties for at least 4000 years. Isolation of the active principle in marijuana, delta9-THC, provided the lead structure in the development of highly potent congeners which were used to probe for the mechanism of marijuana action ...
J, Axelrod, C C, Felder
openaire +2 more sources
Latest advances in cannabinoid receptor agonists
Expert Opinion on Therapeutic Patents, 2009Since the discovery of cannabinoid receptors and their endogenous ligands in early 1990s, the endocannabinoid system has been shown to play a vital role in several pathophysiological processes. It has been targeted for the treatment of several diseases including neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease ...
Ganesh A, Thakur +3 more
openaire +2 more sources
Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists
Biochemical Pharmacology, 2019Cannabinoid receptors type 1 (CB1) and type 2 (CB2) are promising targets for a number of diseases, including obesity, neuropathic pain, and multiple sclerosis, among others. Upon ligand-mediated activation of these receptors, multiple receptor conformations could be stabilized, resulting in a complex pattern of possible intracellular effects. Although
Elise Wouters +3 more
openaire +2 more sources
Recent advances in cannabinoid receptor agonists and antagonists
Expert Opinion on Therapeutic Patents, 2000 This review is an overview of the recent advances in cannabinoid chemistry with a special emphasis on the patent literature. The term cannabinoid includes analogues of the natural components of cannabis, endocannabinoids and a wide array of chemical ...
Nadine Jagerovic
exaly +1 more source
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA [PDF]
ACS Chemical Neuroscience, 2019 Jonathan Javitch +2 more
exaly +2 more sources
Drug Metabolism and Disposition, 2009
Cannabinoid receptor agonist 13 (CRA13) is a novel cannabinoid (CB) receptor agonist with high affinity and functional activity toward both CB(1) and CB(2) receptors. This phase I study aimed to evaluate the pharmacokinetics, safety, and tolerability of single oral doses of CRA13.
Anne, Gardin +3 more
openaire +2 more sources
Cannabinoid receptor agonist 13 (CRA13) is a novel cannabinoid (CB) receptor agonist with high affinity and functional activity toward both CB(1) and CB(2) receptors. This phase I study aimed to evaluate the pharmacokinetics, safety, and tolerability of single oral doses of CRA13.
Anne, Gardin +3 more
openaire +2 more sources